The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials

The introduction of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the management of heart failure with preserved ejection fraction (HFpEF) may be regarded as the first effective treatment in these patients. However, this proposition must be evaluated from the perspective of the complexity of...

Full description

Bibliographic Details
Main Authors:	Luxi Ji, Mudit Mishra, Bart De Geest
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Pharmaceutics
Subjects:	heart failure heart failure with preserved ejection fraction heart failure with reduced ejection fraction sodium-glucose cotransporter-2 (SGLT2) inhibitors clinical outcome endpoints composite endpoints
Online Access:	https://www.mdpi.com/1999-4923/15/4/1092

Similar Items

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
by: Yifang GUO
Published: (2022-06-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines
by: Luca Branca, et al.
Published: (2020-04-01)

Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality
by: Giosafat Spitaleri, et al.
Published: (2022-01-01)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
by: Kaiyuan Zhu, et al.
Published: (2021-07-01)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
by: Gianluigi Savarese, et al.
Published: (2022-08-01)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
by: Sukrit Treewaree, et al.
Published: (2023-02-01)

Diabetes Mellitus and Heart Failure
by: Wun-Zhih Siao, et al.
Published: (2022-10-01)

Editorial: Diabetes and heart failure: basic, translational, and clinical research
by: Laurent Metzinger, et al.
Published: (2023-05-01)

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis
by: Chao Ma, et al.

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01)

Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review
by: Ming-Jui Hung, et al.
Published: (2023-04-01)

Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes
by: Valeria Conti, et al.
Published: (2020-11-01)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
by: Tin‐Kwang Lin, et al.
Published: (2019-06-01)

Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
by: Federico Ferro, et al.
Published: (2022-07-01)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
by: Hallinen T, et al.
Published: (2023-01-01)

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
by: Mayu Tochiya, et al.
Published: (2023-04-01)

Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry
by: Jeehoon Kang, et al.
Published: (2018-03-01)

Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure
by: Anupam Kumar, et al.
Published: (2019-02-01)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
by: Chiara Borrelli, et al.
Published: (2019-09-01)

Association of ambient temperature and acute heart failure with preserved and reduced ejection fraction
by: Takahiro Jimba, et al.
Published: (2022-10-01)

Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
by: Marat Fudim, et al.
Published: (2021-11-01)

Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication
by: Michael Lichtenauer, et al.
Published: (2021-05-01)

Heart failure. The current state of the problem: achievements, frustrations, hopes and prospects
by: E. F. Pavlysh, et al.
Published: (2019-04-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
by: Eiichi Akiyama, et al.
Published: (2020-06-01)

Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
by: Alexander A. Berezin, et al.
Published: (2022-09-01)

Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
by: Hidekatsu Fukuta, et al.
Published: (2022-10-01)

Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction
by: Xin He, et al.
Published: (2021-08-01)

Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
by: Timea Magdolna Szabo, et al.
Published: (2023-03-01)

Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction
by: Liam Gaziano, et al.
Published: (2021-12-01)

Metabolomics and a Breath Sensor Identify Acetone as a Biomarker for Heart Failure
by: Patrick A. Gladding, et al.
Published: (2022-12-01)

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
by: Teja Chakrala, et al.
Published: (2023-04-01)

Relationship Between Dietary Magnesium Intake and Incident Heart Failure Among Older Women: The WHI
by: Wen‐Chih Wu, et al.
Published: (2020-04-01)

A comparison of clinical outcomes following atrial fibrillation ablation for heart failure patients with preserved or reduced left ventricular function: A systematic review and meta-analysis
by: Gaurav Panchal, et al.
Published: (2022-01-01)

Prevalence and Long‐Term Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction
by: Louise Y. Sun, et al.
Published: (2018-06-01)

Circulating sphingolipids in heart failure
by: Anna Kovilakath, et al.
Published: (2023-05-01)

Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update
by: Ioanna Koniari, et al.
Published: (2022-08-01)

Rethinking heart failure clinical trials: the heart failure collaboratory
by: Mutaz Alkalbani, et al.
Published: (2024-01-01)